B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27
Immix Biopharma, Inc.
Immix Biopharma, Inc. IMMX | 0.00 |
B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:
IMMX) with a Buy rating and announces Price Target of $27.
